Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

First Turn Management, LLC

CIK 0001993440
$895.1M
Reported AUM
33
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · First Turn Management, LLC · Q1 2026

AI · grounded in 13F

First Turn Management, LLC closed its position in GH for a reduction of $27.7M. The fund established several new positions, including ELVN for $24.5M and CELC for $24.0M. Additionally, the fund accumulated shares of UTHR, increasing its position by 64.7%.

Portfolio · Q1 2026

UTHR$62.1MABVX$51.9MBBIO$51.7MXENE$45.8MRVMD$45.5MAPGEINSMNUVLMIRMCOGTROIVAXSMOther$378.0MFL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1UTHRUNITED THERAPEUTICS CORP DEL$527.000.44%76.90%142.27%$62.1M6.94%HELD
2ABVXABIVAX SA$121.031.84%65.18%1070.84%$51.9M5.80%HELD
3BBIOBRIDGEBIO PHARMA INC$81.47-2.47%77.69%67.97%$51.7M5.77%HELD
4XENEXENON PHARMACEUTICALS INC$62.73-0.59%106.89%257.51%$45.8M5.11%HELD
5RVMDREVOLUTION MEDICINES INC$184.471.96%393.91%521.93%$45.5M5.09%HELD
6APGEAPOGEE THERAPEUTICS INC$134.15-0.04%255.36%484.79%$43.2M4.83%HELD
7INSMINSMED INC$101.53-1.54%-3.85%272.72%$40.6M4.54%HELD
8NUVLNUVALENT INC0.00%$37.9M4.24%HELD
9MIRMMIRUM PHARMACEUTICALS INC$108.040.44%106.79%561.97%$37.0M4.13%HELD
10COGTCOGENT BIOSCIENCES INC$39.890.81%247.33%378.21%$36.5M4.07%HELD
11ROIVROIVANT SCIENCES LTD$33.241.13%196.20%236.68%$33.0M3.68%HELD
12AXSMAXSOME THERAPEUTICS INC.$230.011.14%121.03%782.79%$31.9M3.56%HELD
13IDYAIDEAYA BIOSCIENCES INC$35.670.22%46.64%51.45%$29.1M3.25%HELD
14ORICORIC PHARMACEUTICALS INC$11.19-0.81%11.46%-48.94%$25.6M2.86%HELD
15ELVNENLIVEN THERAPEUTICS INC$53.060.17%182.81%176.46%$24.5M2.73%HELD
16CELCCELCUITY INC$84.161.08%108.62%278.45%$24.0M2.69%HELD
17SRRKSCHOLAR ROCK HLDG CORP$49.170.21%34.93%24.11%$21.9M2.45%HELD
18KYMRKYMERA THERAPEUTICS INC$104.75-0.48%143.32%68.22%$21.2M2.37%HELD
19CYTKCYTOKINETICS INC$79.221.06%115.51%139.82%$18.7M2.09%HELD
20DNTHDIANTHUS THERAPEUTICS INC$106.752.56%405.54%1.65%$18.5M2.07%HELD
21PVLAPALVELLA THERAPEUTICS INC NE$145.902.31%283.01%-67.53%$18.5M2.06%HELD
22NAMSNEWAMSTERDAM PHARMA COMPANY$27.30-2.19%31.16%188.92%$17.9M2.00%HELD
23VRDNVIRIDIAN THERAPEUTICS INC$19.40-2.44%14.19%48.58%$17.8M1.99%HELD
24ASNDUSDASCENDIS PHARMA A/S$17.5M1.95%HELD
25FULCFULCRUM THERAPEUTICS INC$3.661.10%-47.00%-87.81%$17.3M1.93%HELD
26430TERNS PHARMACEUTICALS INC$17.2M1.92%HELD
27VERAVERA THERAPEUTICS INC$32.881.14%55.85%121.51%$17.0M1.90%HELD
28NTRANATERA INC$255.960.84%88.60%114.32%$16.2M1.81%HELD
29ERASERASCA INC$18.011.64%1174.82%-25.89%$14.0M1.57%HELD
30PRAXPRAXIS PRECISION MEDICINES I$302.373.90%451.22%0.04%$13.7M1.53%HELD
31OLMAOLEMA PHARMACEUTICALS INC$11.12-0.63%$11.5M1.28%HELD
32QUREUNIQURE NV$41.353.19%$10.1M1.12%HELD
33MLTXMOONLAKE IMMUNOTHERAPEUTICS$18.540.87%$5.9M0.66%HELD

Source: SEC EDGAR · accession 0001993440-26-000002. 13F discloses long positions only — shorts, foreign equities, and options are excluded.